Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Item

http://www.wikidata.org/entity/Q35209369

Q35209369

about

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Novel therapies for the treatment of advanced prostate cancer.Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.A new simple and high-yield synthesis of 5α-dihydrotestosterone (DHT), a potent androgen receptor agonist.Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.Anticancer steroids: linking natural and semi-synthetic compounds.The evolution of prostate cancer therapy: targeting the androgen receptor Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.Androgen receptor variation affects prostate cancer progression and drug resistance.Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model.Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.

P2860

Q26740070-88319E54-13A8-49DD-830C-8D96072BA121 Q33621403-239647A1-FFFA-4AC3-BAD9-789C6B6E1194 Q33775717-150FB976-CD5B-4184-BF69-BC1A3D30FA68 Q34387852-48D82AE7-A21E-44D5-B625-653082E7DD87 Q34424735-35BCB007-23BF-4B63-8AD8-00115135AF35 Q34525556-00938B5C-374D-425E-BF64-63727BC867ED Q36297428-F6B8CA7A-A63E-4C66-93D5-CA2B0C2CF92A Q36413805-524A0EF6-FC6A-4682-A3AA-8C61A85F2470 Q36665708-EF531729-1E32-43D6-9557-CCAF867F1E84 Q37076775-AF81448F-E7C9-4E32-8122-24ADBBF44F3C Q37648775-C7206FB3-59AC-4747-9C82-AE44B6ABD113 Q37656304-1821C372-48AD-493E-9B42-BFC32EE5892F Q37950948-69A3524E-2C01-40FB-9D53-D484FEBC5E0C Q38059807-353FF99B-4DA0-4FDE-BD06-E3AAE728300C Q38266909-ADC429B5-5808-4795-8660-2C25032D7E27 Q38361928-AE4B7451-21D8-47D0-A0DC-C60C7DFFEABD Q38977288-5E8B31DC-DDA4-4B73-9685-E9033737597C Q41812923-4D0D5D34-6761-4E1B-A5AE-518BC81DA050 Q42123839-BAC9B54D-B957-4645-B535-1DDB721617B2 Q47104372-29DC9E16-EE7A-4F87-94E4-A1F4BB1257C4 Q50925353-A0688BF7-0B1B-4CCB-B6CD-9A812AD961B1 Q55129906-B41F68DF-B78A-40E3-80EC-069BE79D7C64 Q55262957-D060FC70-BDFA-4786-AE1B-6759D60CA28E

P2860

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Item

http://www.wikidata.org/entity/Q35209369

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu